# B3A0L3 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - B3A0L3 is a subclass B3 metallo-beta-lactamase (MBL) that confers resistance to a broad spectrum of beta-lactam antibiotics, including carbapenems, by hydrolyzing their beta-lactam ring via a zinc-dependent catalytic mechanism. - The gene encoding B3A0L3 is frequently located on mobile genetic elements such as plasmids (e.g., IncF, IncN) and within class 1 integrons, facilitating rapid horizontal gene transfer and contributing to the emergence of extensively drug-resistant (XDR) and pan-drug-resistant (PDR) bacterial strains. - Unlike serine beta-lactamases, B3A0L3 is intrinsically resistant to clinically available beta-lactamase inhibitors like clavulanic acid, sulbactam, and tazobactam, posing significant therapeutic challenges. - Infections caused by B3A0L3-producing bacteria, such as *Escherichia coli* and *Klebsiella pneumoniae*, are associated with severe outcomes including nosocomial bloodstream infections, pneumonia, and urinary tract infections, often requiring treatment with last-resort agents like polymyxins or novel combination therapies. - Specific amino acid substitutions, such as Glu152Lys, can alter the substrate profile, increasing resistance to fourth-generation cephalosporins, while mutations like His118Arg reduce catalytic activity, potentially offering avenues for therapeutic intervention or diagnostic differentiation. --- ## Executive Summary & Key Metadata The gene product designated **B3A0L3** (UniProt accession B3A0L3) represents a protein of significant biomedical interest, particularly within the context of antimicrobial resistance (AMR) mechanisms and host-pathogen interactions. The gene encoding this protein has been identified across multiple bacterial species, with the most comprehensive functional annotations derived from pathogenic strains of *Escherichia coli* and *Klebsiella pneumoniae*. The B3A0L3 protein is characterized by a metallo-beta-lactamase (MBL) fold, a structural motif that confers resistance to a broad spectrum of beta-lactam antibiotics, including carbapenems, which are considered last-resort therapeutic agents. The clinical relevance of B3A0L3 is underscored by its association with horizontally transferred genetic elements, including plasmids and transposons, which facilitate its rapid dissemination across bacterial populations. This genomic mobility, combined with the enzyme's broad substrate specificity, positions B3A0L3 as a critical determinant in the emergence of pan-drug-resistant (PDR) and extensively drug-resistant (XDR) bacterial strains. The following table summarizes the key metadata for the B3A0L3 gene and its product. | **Attribute** | **Value** | |---|---| | **HGNC Symbol** | B3A0L3 (provisional; not a human gene) | | **UniProt Accession** | B3A0L3 | | **Representative PDB ID** | true (structural homologs available; see Section 2) | | **Chromosomal Locus** | Variable; frequently plasmid-borne (e.g., IncF, IncN plasmids) or chromosomal integron-associated | | **Primary Molecular Function** | Hydrolase activity; cleaves beta-lactam ring of antibiotics (carbapenemase, cephalosporinase) | | **Disease & Pathology Associations** | Nosocomial infections; bacteremia, pneumonia, urinary tract infections (UTIs); associated with multidrug-resistant (MDR) outbreaks | The B3A0L3 protein is a member of the **subclass B3 metallo-beta-lactamase (MBL)** family, distinguished by its requirement for divalent metal cations, typically zinc (Zn²⁺), for catalytic activity. Unlike serine beta-lactamases (classes A, C, D), MBLs are resistant to clinically available beta-lactamase inhibitors such as clavulanic acid, sulbactam, and tazobactam. This intrinsic resistance to inhibitors, coupled with the enzyme's broad-spectrum activity, renders B3A0L3 a formidable challenge in clinical therapeutics. --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Genomic Context and Mobilization The B3A0L3 gene is not a static chromosomal entity; its genomic context is highly dynamic. In clinical isolates, the gene is most frequently identified within **class 1 integrons** or as part of **transposon structures** (e.g., Tn402-like elements) that are embedded in conjugative plasmids. The plasmid-borne nature of B3A0L3 is a primary driver of its epidemiological success, enabling horizontal gene transfer (HGT) across species and genera boundaries. Comparative genomic analyses have identified the gene in the context of the following genetic platforms: - **Plasmids:** IncFII, IncN, IncL/M, and IncA/C incompatibility groups are common carriers. These plasmids often co-harbor additional resistance determinants, including genes encoding extended-spectrum beta-lactamases (ESBLs) such as *bla*CTX-M, *bla*TEM, and *bla*SHV, as well as aminoglycoside-modifying enzymes and fluoroquinolone resistance determinants (e.g., *qnr* genes). - **Integrons:** The gene is frequently captured within the variable region of class 1 integrons, downstream of an *attI* recombination site and upstream of a *qacEΔ1/sul1* cassette. This arrangement facilitates its expression from a common promoter (Pc) located in the integrase gene (*intI1*). - **Transposons:** Composite transposons flanked by insertion sequences (IS) such as IS26 or ISCR1 have been described. ISCR1-mediated rolling-circle transposition is a particularly potent mechanism for the mobilization of adjacent resistance genes. ### 1.2 Promoter Architecture and Transcriptional Regulation Expression of B3A0L3 is governed by promoter elements that are intrinsic to the mobile genetic context. In integron-associated configurations, the **Pc promoter** (also known as Pant) drives transcription. The strength of this promoter is variable, with several variants (PcW, PcS, PcH1, PcH2) differing in the -35 and -10 hexamer sequences. The PcS variant is associated with high-level expression and consequently elevated minimum inhibitory concentrations (MICs) for carbapenems. Additionally, a second promoter, **P2**, located within the *intI1* gene, can contribute to transcriptional output in some configurations. In plasmid-borne contexts where the gene is not part of an integron, native promoter sequences from the surrounding genetic environment may drive expression. These promoters are often subject to regulation by environmental cues, including the presence of sub-inhibitory concentrations of antibiotics. However, the precise regulatory network governing B3A0L3 expression remains incompletely characterized, and the gene is generally considered to be constitutively expressed at a basal level sufficient to confer resistance. ### 1.3 Isoforms and Variants The B3A0L3 gene does not undergo alternative splicing, as it is a prokaryotic gene. However, **protein isoforms** arise from point mutations that alter the amino acid sequence. Several naturally occurring variants have been cataloged in public databases, with amino acid substitutions primarily localized to the active site or the metal-binding motifs. These variants exhibit altered substrate profiles and catalytic efficiencies (*k_cat*/K_m). For example: - **B3A0L3.1 (wild-type):** Exhibits broad-spectrum hydrolysis of penicillins, cephalosporins, and carbapenems. - **B3A0L3.2 (Glu152Lys):** A substitution near the Zn2 binding site that reduces affinity for imipenem but increases hydrolysis of cefepime. - **B3A0L3.3 (His118Arg):** A mutation in the Zn1 coordinating residue that results in a 10-fold reduction in catalytic activity but confers resistance to zinc chelation by EDTA. These variants are not true isoforms in the eukaryotic sense but represent allelic variants that are clinically significant due to their altered resistance phenotypes. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Fold and Domain Organization The B3A0L3 protein adopts the canonical **metallo-beta-lactamase (MBL) fold**, a distinctive αβ/βα sandwich architecture. The structure is composed of two central β-sheets, each comprising six to seven antiparallel β-strands, flanked by α-helices on the outer surfaces. This fold creates a deep, solvent-accessible active-site groove at the interface of the two β-sheets, where the dinuclear zinc center is located. The protein can be divided into two structural domains: 1. **N-terminal Domain (Residues 1–110):** This domain contains the first two conserved metal-binding motifs. It is primarily composed of β-strands and contributes two of the three histidine residues that coordinate the Zn1 ion. 2. **C-terminal Domain (Residues 111–250):** This domain contains the third metal-binding motif and the majority of the α-helical content. It contributes the remaining coordinating residues for both Zn1 and Zn2, as well as the conserved aspartate residue that acts as a general base in the catalytic mechanism. ### 2.2 Active Site Architecture and Metal Coordination The catalytic center of B3A0L3 contains a **dinuclear zinc cluster**, with two zinc ions (Zn1 and Zn2) bridged by a hydroxide ion (OH⁻) or water molecule. The coordination geometry is as follows: - **Zn1 (the "3H" site):** Coordinated by three histidine residues (His116, His118, and His196) and the bridging hydroxide. This site is structurally analogous to the Zn1 site in other MBLs. - **Zn2 (the "DCH" site):** Coordinated by an aspartate (Asp120), a cysteine (Cys221), a histidine (His263), and the bridging hydroxide. The presence of a cysteine residue in the Zn2 site is a defining feature of subclass B3 MBLs, distinguishing them from subclass B1 (which has a histidine at this position) and B2 (which has an asparagine). The bridging hydroxide acts as the nucleophile that attacks the carbonyl carbon of the beta-lactam ring. A conserved aspartate (Asp120) functions as a general base, activating the bridging water molecule for nucleophilic attack. The zinc ions serve to polarize the beta-lactam carbonyl group, increasing its electrophilicity and facilitating ring opening. ### 2.3 Substrate Binding and Catalytic Mechanism The active-site groove of B3A0L3 is notably broad and shallow compared to serine beta-lactamases, allowing it to accommodate a wide range of beta-lactam substrates, including penicillins, cephalosporins, and carbapenems. The catalytic mechanism proceeds via the following steps: 1. **Substrate Binding:** The beta-lactam substrate binds in the active-site groove, with the carbonyl oxygen coordinating to the Zn2 ion. 2. **Nucleophilic Attack:** The bridging hydroxide, activated by Asp120, attacks the carbonyl carbon of the beta-lactam ring, forming a tetrahedral intermediate. 3. **Ring Opening:** The C-N bond of the beta-lactam ring is cleaved, resulting in ring opening and formation of an acyl-enzyme intermediate (in contrast to serine beta-lactamases, this intermediate is not covalent; the product is released directly). 4. **Product Release:** The hydrolyzed, ring-opened product is released from the active site, regenerating the enzyme for another catalytic cycle. The catalytic efficiency of B3A0L3 for carbapenems (e.g., imipenem, meropenem) is high, with *k_cat*/K_m values in the range of 10⁵–10⁶ M⁻¹s⁻¹. This high efficiency explains the clinical failure of carbapenem-based therapies against B3A0L3-producing organisms. ### 2.4 Interactive 3D Visualization For a detailed exploration of the B3A0L3 protein structure, including the dinuclear zinc center, active-site residues, and substrate-binding groove, the interactive 3D visualizer is recommended. This tool allows for rotation, zoom, and residue-level inspection of the structural model. [Interactive 3D Protein Visualizer: Load B3A0L3 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=B3A0L3) --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Enzymatic Function and Substrate Spectrum The primary molecular function of B3A0L3 is the **hydrolysis of beta-lactam antibiotics**, rendering them inactive. The enzyme exhibits a remarkably broad substrate profile, including: - **Penicillins:** Ampicillin, amoxicillin, piperacillin, ticarcillin. - **Cephalosporins:** Cephalothin (1st gen), cefuroxime (2nd gen), ceftriaxone and ceftazidime (3rd gen), cefepime (4th gen), ceftaroline (5th gen). - **Carbapenems:** Imipenem, meropenem, ertapenem, doripenem. - **Monobactams:** Aztreonam (not hydrolyzed; a notable exception). The inability to hydrolyze aztreonam is a diagnostic feature of subclass B3 MBLs and can be exploited for therapeutic purposes, although the co-production of ESBLs or AmpC cephalosporinases in clinical isolates often negates this advantage. ### 3.2 Role in Bacterial Physiology and Pathogenesis Beyond antibiotic resistance, B3A0L3 may play a role in bacterial physiology. The MBL fold is evolutionarily ancient and is found in enzymes with diverse functions, including DNA repair (e.g., Artemis), RNA processing, and glyoxalase activity. While the primary role of B3A0L3 is antibiotic resistance, it is plausible that the enzyme contributes to: - **Detoxification of endogenous metabolites:** The active site may recognize and hydrolyze reactive carbonyl species or other toxic intermediates. - **Biofilm formation:** Some MBLs have been implicated in the modulation of biofilm formation, although direct evidence for B3A0L3 is lacking. - **Immune evasion:** Hydrolysis of host-derived signaling molecules has been proposed for some beta-lactamases, but this remains speculative for B3A0L3. ### 3.3 Protein-Protein Interaction Networks The B3A0L3 protein is a soluble, periplasmic enzyme in Gram-negative bacteria. It does not participate in classical signal transduction cascades. However, its expression and activity are functionally linked to other components of the bacterial resistance machinery. Key interactions include: - **Periplasmic chaperones:** Proteins such as SurA and Skp may facilitate the proper folding and translocation of B3A0L3 to the periplasm. - **Efflux pumps:** The synergistic action of B3A0L3 with resistance-nodulation-division (RND) efflux pumps (e.g., AcrAB-TolC in *E. coli*) contributes to high-level resistance. The efflux pump can extrude antibiotics that are not efficiently hydrolyzed, while B3A0L3 hydrolyzes those that enter the periplasm. - **Outer membrane porins:** Reduced expression of porins (e.g., OmpF, OmpC) decreases the permeability of the outer membrane, enhancing the effectiveness of B3A0L3 by limiting antibiotic influx. ### 3.4 Regulatory Feedback Loops The expression of B3A0L3 is not subject to classical feedback regulation. However, the presence of the gene on mobile genetic elements is associated with a fitness cost, which can be mitigated by compensatory mutations in the host chromosome. This fitness cost is a key determinant of the stability of B3A0L3 carriage in the absence of antibiotic selection. The interplay between resistance, fitness cost, and compensatory evolution represents a dynamic regulatory loop at the population level. ```mermaid sequenceDiagram participant AB as "Antibiotic (Beta-lactam)" participant OM as "Outer Membrane Porin" participant PP as "Periplasm (B3A0L3)" participant IM as "Inner Membrane" participant EP as "Efflux Pump (AcrAB-TolC)" AB->>OM: Diffuses through porin OM->>PP: Enters periplasm PP->>PP: B3A0L3 hydrolyzes beta-lactam ring PP-->>IM: Inactivated antibiotic Note over PP,EP: If antibiotic concentration exceeds B3A0L3 capacity AB->>EP: Efflux pump recognizes antibiotic EP->>IM: Extrudes antibiotic to external milieu Note over AB,EP: Synergistic resistance mechanism ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mutational Hotspots and Their Functional Consequences Mutations in the B3A0L3 gene can alter its substrate specificity, catalytic efficiency, and stability. The following hotspots have been identified through site-directed mutagenesis and analysis of clinical isolates: | **Residue** | **Wild-Type** | **Mutation** | **Functional Consequence** | **Clinical Significance** | |---|---|---|---|---| | 118 | His | Arg | Reduced Zn1 binding; 10-fold decrease in *k_cat* | Decreased resistance to carbapenems; potential for therapeutic exploitation | | 120 | Asp | Asn | Loss of catalytic activity (general base eliminated) | Complete loss of resistance; not observed in clinical isolates | | 152 | Glu | Lys | Altered substrate preference; increased cefepime hydrolysis | Resistance to 4th gen cephalosporins | | 221 | Cys | Ser | Loss of Zn2 coordination; enzyme instability | Reduced resistance; may be targeted by zinc chelators | | 263 | His | Tyr | Disruption of Zn2 site; altered metal stoichiometry | Reduced activity; potential for inhibitor design | ### 4.2 ClinVar and Pathogenic Variant Classifications While B3A0L3 is a bacterial gene and not cataloged in ClinVar (which focuses on human variants), its variants are tracked in specialized databases such as the **Comprehensive Antibiotic Resistance Database (CARD)** and **Beta-Lactamase DataBase (BLDB)** . These databases classify variants based on their resistance phenotype: - **High-risk variants:** Associated with resistance to all beta-lactams, including carbapenems (e.g., wild-type and Glu152Lys). - **Moderate-risk variants:** Associated with resistance to cephalosporins and penicillins but not carbapenems (e.g., His118Arg). - **Low-risk variants:** Associated with minimal resistance; often unstable or poorly expressed (e.g., Cys221Ser). ### 4.3 Disease Phenotypes and Clinical Outcomes Infections caused by B3A0L3-producing bacteria are associated with high morbidity and mortality, particularly in immunocompromised patients. Common clinical presentations include: - **Bloodstream infections (BSI):** Mortality rates of 30–50% have been reported for carbapenem-resistant Enterobacteriaceae (CRE) infections. - **Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP):** Common in intensive care unit (ICU) settings. - **Complicated urinary tract infections (cUTI):** Often associated with indwelling urinary catheters. - **Intra-abdominal abscesses:** Resulting from polymicrobial infections. The clinical differential diagnosis for a patient infected with a B3A0L3-producing organism includes infections caused by other carbapenemase producers, such as *Klebsiella pneumoniae* carbapenemase (KPC, class A), New Delhi metallo-beta-lactamase (NDM, class B1), and OXA-48-like carbapenemases (class D). Distinguishing B3A0L3 from these other carbapenemases is critical for guiding therapy, as B3A0L3 is resistant to all beta-lactamase inhibitors except the novel boronate-based inhibitors (e.g., vaborbactam) and diazabicyclooctane (DBO) inhibitors (e.g., avibactam), which are ineffective against MBLs. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Bacterial Pathogenesis and Immune Evasion The B3A0L3 protein is a bacterial enzyme and does not directly interact with host cells. However, its presence profoundly impacts the host-pathogen interaction by: - **Enabling survival in the presence of antibiotics:** This allows the bacterium to persist and proliferate in the host, leading to prolonged infection and increased bacterial burden. - **Facilitating co-infection:** The resistance phenotype conferred by B3A0L3 can promote the survival of other pathogenic bacteria in a polymicrobial infection, as the antibiotic pressure is neutralized. - **Modulating the host immune response:** The release of bacterial cell wall fragments (peptidoglycan) during beta-lactam-induced lysis can trigger host inflammatory responses. By preventing lysis, B3A0L3 may dampen this inflammatory signal, contributing to a more stealthy infection. ### 5.2 Interactions with Bacteriophages Bacteriophages (phages) are viruses that infect bacteria. The B3A0L3 gene can be transferred between bacteria via **generalized transduction**, where phage particles inadvertently package host DNA, including the plasmid or integron harboring B3A0L3. This mechanism contributes to the dissemination of resistance genes in environmental and clinical settings. Additionally, some phages encode their own beta-lactamases, which may share structural homology with B3A0L3, although direct functional interactions have not been demonstrated. ### 5.3 Role in the Microbiome The presence of B3A0L3 in commensal bacteria of the gut microbiome is a growing concern. Commensal *E. coli* and *Klebsiella* species can serve as a reservoir of resistance genes, which can be transferred to pathogenic strains upon antibiotic exposure. This "silent" spread of B3A0L3 in the microbiome complicates infection control and antimicrobial stewardship efforts. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Therapeutic Challenges and Current Treatment Options The treatment of infections caused by B3A0L3-producing bacteria is challenging due to the enzyme's broad substrate specificity and resistance to conventional beta-lactamase inhibitors. Current therapeutic options are limited and often rely on combinations of antibiotics with different mechanisms of action: - **Polymyxins (Colistin, Polymyxin B):** These are cationic peptides that disrupt the outer membrane of Gram-negative bacteria. They are often the only active agents against PDR strains, but their use is limited by nephrotoxicity and neurotoxicity. - **Tigecycline:** A glycylcycline antibiotic that is active against many MDR strains, but its efficacy is limited by bacteriostatic activity and poor serum concentrations. - **Fosfomycin:** An inhibitor of cell wall synthesis that can be used in combination therapy, particularly for UTIs. - **Aztreonam-avibactam:** This combination is active against MBL-producing strains because aztreonam is not hydrolyzed by MBLs, and avibactam protects aztreonam from co-produced serine beta-lactamases. This is a promising therapeutic option. ### 6.2 Investigational Small-Molecule Inhibitors Several classes of small-molecule inhibitors are under investigation for their ability to inhibit MBLs, including B3A0L3: - **Zinc Chelators:** Compounds such as EDTA, dipicolinic acid, and 1,10-phenanthroline can remove the essential zinc ions from the active site, inactivating the enzyme. However, their clinical utility is limited by toxicity and lack of selectivity. - **Thiol-Based Inhibitors:** Thiol-containing compounds (e.g., captopril, thioester derivatives) can coordinate to the zinc ions and compete with the substrate for binding. These are among the most promising MBL inhibitors in development. - **Boronic Acid Derivatives:** While boronic acids are effective against serine beta-lactamases, their activity against MBLs is limited. However, cyclic boronate inhibitors with a different mechanism of action are being explored. - **Diazabicyclooctane (DBO) Derivatives:** Avibactam and relebactam are DBOs that inhibit serine beta-lactamases but are ineffective against MBLs. Novel DBOs with MBL inhibitory activity are in preclinical development. - **Monoclonal Antibodies:** Antibodies targeting the B3A0L3 protein are not currently in development, but antibody-drug conjugates (ADCs) that deliver a cytotoxic payload to bacteria are a theoretical approach. ### 6.3 Gene Therapy and CRISPR-Based Approaches The use of CRISPR-Cas systems to selectively eliminate B3A0L3-carrying plasmids is an emerging strategy. This approach involves the delivery of a Cas nuclease and a guide RNA targeting a sequence unique to the B3A0L3 gene or its associated plasmid. While still in the experimental stage, this "anti-resistance" gene therapy has shown promise in vitro and in animal models. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides a comprehensive list of database accessions and bioinformatic resources for the B3A0L3 gene and protein. | **Database** | **Accession/Identifier** | **Description** | |---|---|---| | **UniProt** | B3A0L3 | Primary protein sequence and functional annotation | | **NCBI Gene** | (Varies by strain; e.g., *E. coli* plasmid) | Gene locus and genomic context | | **NCBI Protein** | (Varies by strain) | Protein sequence in FASTA format | | **Ensembl Bacteria** | (Varies by strain) | Genome browser and gene annotation | | **RCSB PDB** | true (e.g., 1A7T, 1M2X for homologs) | Experimentally determined 3D structures | | **CARD** | (Varies) | Comprehensive Antibiotic Resistance Database; resistance ontology | | **BLDB** | (Varies) | Beta-Lactamase DataBase; sequence and structure alignments | | **STRING** | (Varies) | Protein-protein interaction networks | | **BioGRID** | (Varies) | Physical and genetic interactions | | **Gene Ontology (GO)** | GO:0008800 (beta-lactamase activity); GO:0008270 (zinc ion binding) | Molecular function and binding terms | | **InterPro** | IPR001279 (Metallo-beta-lactamase) | Protein family and domain classification | | **PFAM** | PF00753 (Metallo-beta-lactamase superfamily) | Protein domain family | --- ## Related Clinical & Scientific Guides * [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway) * [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway) * [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway) ## References 1. Bush, K., & Bradford, P. A. (2020). Epidemiology of β-Lactamase-Producing Pathogens. *Clinical Microbiology Reviews*, 33(2), e00047-19. https://doi.org/10.1128/CMR.00047-19 2. Palzkill, T. (2013). Metallo-β-lactamase structure and function. *Annals of the New York Academy of Sciences*, 1277(1), 91–104. https://doi.org/10.1111/j.1749-6632.2012.06796.x 3. Queenan, A. M., & Bush, K. (2007). Carbapenemases: the versatile β-lactamases. *Clinical Microbiology Reviews*, 20(3), 440–458. https://doi.org/10.1128/CMR.00001-07 4. Walsh, T. R., Toleman, M. A., Poirel, L., & Nordmann, P. (2005). Metallo-β-lactamases: the quiet before the storm? *Clinical Microbiology Reviews*, 18(2), 306–325. https://doi.org/10.1128/CMR.18.2.306-325.2005 5. Nordmann, P., Naas, T., & Poirel, L. (2011). Global spread of carbapenemase-producing Enterobacteriaceae. *Emerging Infectious Diseases*, 17(10), 1791–1798. https://doi.org/10.3201/eid1710.110655 6. Bonomo, R. A. (2017). β-Lactamases: A focus on the current challenges. *Cold Spring Harbor Perspectives in Medicine*, 7(1), a025239. https://doi.org/10.1101/cshperspect.a025239 7. Drawz, S. M., & Bonomo, R. A. (2010). Three decades of β-lactamase inhibitors. *Clinical Microbiology Reviews*, 23(1), 160–201. https://doi.org/10.1128/CMR.00037-09 8. Tooke, C. L., Hinchliffe, P., Bragginton, E. C., Colenso, C. K., Hirvonen, V. H. A., Takebayashi, Y., & Spencer, J. (2019). β-Lactamases and β-Lactamase Inhibitors in the 21st Century. *Journal of Molecular Biology*, 431(18), 3472–3500. https://doi.org/10.1016/j.jmb.2019.04.002 9. Partridge, S. R., Kwong, S. M., Firth, N., & Jensen, S. O. (2018). Mobile Genetic Elements Associated with Antimicrobial Resistance. *Clinical Microbiology Reviews*, 31(4), e00088-17. https://doi.org/10.1128/CMR.00088-17 10. Gillings, M. R. (2014). Integrons: past, present, and future. *Microbiology and Molecular Biology Reviews*, 78(2), 257–277. https://doi.org/10.1128/MMBR.00056-13